Camber Pharmaceuticals, Inc.

01/29/2025

Camber Pharmaceuticals is excited to announce the addition of Sirolimus Oral Solution.

Sirolimus Oral Solution is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged greater or equal to 13 years, receiving renal transplants.

* Patients at low to moderate immunologic risk: use initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is recommended 2 to 4 months after transplantation.
* Patients at high immunologic risk: use in combination with CsA and corticosteroids

Sirolimus Oral Solution 1 mg/mL is now available in a 60 mL bottle.

To find out more information on Sirolimus Oral Solution, please visit: www.camberpharma.com/sirolimus

https://conta.cc/3PTtejk

Email from Camber Pharmaceuticals, Inc. New Product Launch View as Webpage Camber Launches Sirolimus Oral Solution Piscataway, NJ, January 29, 2025 –Camber Pharmaceuticals is excited to announce the a

01/10/2025

Camber Pharmaceuticals is excited to announce the addition of Nimodipine Oral Solution.

Nimodipine Oral Solution is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition.

Nimodipine Oral Solution 60 mg/20 mL (3 mg/mL) is available and packaged in a 16-ounce bottle.

To find out more information on Nimodipine Oral Solution, please visit: www.camberpharma.com/nimodipine

https://conta.cc/40rrnbz

01/07/2025

Camber Pharmaceuticals is excited to announce the addition of Bortezomib for Injection.

Bortezomib for Injection is a proteasome inhibitor indicated for:
1. treatment of adult patients with multiple myeloma
2. treatment of adult patients with mantle cell lymphoma

Bortezomib for Injection is available in 3.5 mg strength, packaged in a single-dose vial.

To find out more information on Bortezomib for Injection please visit: www.camberpharma.com/bortezomib

https://conta.cc/3DLWGVM

Email from Camber Pharmaceuticals, Inc. New Product Launch View as Webpage Camber Launches Generic Velcade® Piscataway, NJ, January 7, 2024 –Camber Pharmaceuticals is excited to announce the addition

12/27/2024

Camber Pharmaceuticals is excited to announce the addition of Dicyclomine Hydrochloride Capsules, USP.

Dicyclomine Hydrochloride Capsules, USP are an antispasmodic and anticholinergic (antimuscarinic) agent indicated for the treatment of functional bowel/irritable bowel syndrome.

Dicyclomine Hydrochloride Capsules, USP are available in 10 mg strength, packaged in 100 and 1000 count bottles.

To find out more information on Dicyclomine Hydrochloride Capsules, USP please visit: www.camberpharma.com/dicyclominecapsules

https://conta.cc/4a2B4R5

Email from Camber Pharmaceuticals, Inc. New Product Launch View as Webpage Camber Launches Generic Bentyl® Piscataway, NJ, December 27, 2024 –Camber Pharmaceuticals is excited to announce the addition

12/03/2024

Camber Pharmaceuticals is excited to announce the addition of Decitabine for Injection.

Decitabine for Injection is indicated for treatment of:

*adult patients with myelodysplastic syndromes (MDS)
*de novo and secondary MDS of all French-American British subtypes
*refractory anemia with excess blasts
*chronic myelomonocytic leukemia

Decitabine for Injection is available in a 50 mg Single-Dose Vial.

To find out more information on Decitabine for Injection please visit: https://www.camberpharma.com/products/decitabine-lyophilized/

https://conta.cc/41fbpCk

12/03/2024

Camber Pharmaceuticals is excited to introduce Lidocaine HCl Injection, USP, in Single-Dose and Multi-Dose Vials.

Featuring 1% and 2% concentrations, this versatile product is available in various vial and pack sizes to meet diverse healthcare needs.

https://conta.cc/4gcXMI2

10/29/2024

Camber Pharmaceuticals is excited to expand its product line with Avanafil Tablets. A study by the Cleveland Clinic reveals that about 40% of men experience erectile dysfunction (ED) by age 40, with this number rising to nearly 70% by age 70. Avanafil Tablets is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction.

Avanafil Tablets is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction.

Avanafil Tablets are available in 50, 100 and 200 mg strengths in 30 count bottles.

https://conta.cc/40nMoo5

10/17/2024

Approximately 3.2 million Americans are affected by schizophrenia, while 5.7 million struggle with bipolar disorders. Camber Pharmaceuticals is proud to expand its product line with Quetiapine Tablets, USP, offering patients a more affordable, high-quality treatment option. This addition supports our ongoing commitment to reducing drug shortages and improving access to essential medications.

For more information on Quetiapine Tablets please visit us at:
https://www.camberpharma.com/camber-launches-generic-seroquel/

https://conta.cc/402PKwG

Email from Camber Pharmaceuticals, Inc. New Product Launch View as Webpage Camber Pharmaceuticals Launches Generic Seroquel® Piscataway, NJ, October 17, 2024 – Approximately 3.2 million Americans are

10/10/2024

Camber Pharmaceuticals is pleased to announce the addition of Ketorolac Tromethamine Injection, USP to its product line.

Ketorolac Tromethamine Injection, USP is indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level.

Ketorolac Tromethamine Injection, USP is available in:

15 mg/ mL | 10 x 1 mL Single- Dose Vials
15 mg/ mL | 25 x 1 mL Single- Dose Vials
30 mg/ mL | 25 x 1 mL Single- Dose Vials
60 mg/ mL | 25 x 2 mL Single- Dose Vials

To learn more about Ketorolac Tromethamine Injection, USP, please visit https://www.camberpharma.com/ketorolacinjection

10/02/2024

Camber Pharmaceuticals is pleased to announce the addition of Eszopiclone Tablets, USP to its product line. Between 50 and 70 million Americans suffer from chronic sleep disorders. Sleep deprivation can result in physical and mental health issues, increased risk of injury, reduced productivity, and even a higher chance of mortality.

Eszopiclone Tablets, USP are indicated for the treatment of insomnia. They have been shown to decrease sleep latency and improve sleep maintenance.

Eszopiclone Tablets, USP, are available in 1, 2, and 3 mg strengths in 30 and 100 count bottles.

To learn more about Eszopiclone Tablets, USP, please visit www.camberpharma.com/products/eszopiclone

https://conta.cc/3zQsc3d

New Product Launch View as Webpage Camber Pharmaceuticals Launches Generic Lunesta® Piscataway, NJ, October 2, 2024 - Camber Pharmaceuticals is pleased to announce the addition of Eszopiclone Tablets

05/16/2024

Camber Pharmaceuticals is thrilled to announce the addition of Rufinamide Oral Suspension to its product line. Following the launch of Rufinamide Tablets in 2021, this new addition completes the Rufinamide product family.

Rufinamide Oral Suspension is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.

Rufinamide Oral Suspension 40 mg/mL is available in a 460 mL bottle with child-resistant closure along with two calibrated oral dosing syringes and an adapter.

04/26/2024

Camber Pharmaceuticals is thrilled to announce the addition of Aripiprazole Oral Solution to its product line, complementing the existing product family that included Aripiprazole Tablets. Camber initially launched Aripiprazole Tablets in 2015, as one of the first generic alternatives to Abilify®, significantly expanding patient access to this life-changing medication.

Aripiprazole Oral Solution is indicated for the treatment of:
• Schizophrenia
• Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder
• Irritability Associated with Autistic Disorder
• Treatment of Tourette’s Disorder

Aripiprazole Oral Solution 1 mg/mL is available in 150 mL child-resistant bottles along with a calibrated oral dosing cup.

To learn more about Aripiprazole Oral Solution, please visit https://www.camberpharma.com/aripiprazole-oral-sol

https://conta.cc/3wl2phT

04/17/2024

Camber Pharmaceuticals is excited to introduce Fesoterodine Fumarate Extended-Release Tablets.

According to the Cleveland Clinic, approximately 33 million Americans struggle with overactive bladders, impacting about 30% of adult males and 40% of adult females nationwide.

Fesoterodine Fumarate ER Tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency.

Fesoterodine Fumarate ER Tablets are available in 30 count bottles in 4 mg and 8 mg strengths.

To learn more about Fesoterodine Fumarate Extended- Release Tablets, please visit https://www.camberpharma.com/fesoterodine-fumarate-er

https://conta.cc/3xDiakP

New Product Launch   Camber Pharmaceuticals Launches Generic Toviaz® Piscataway, NJ, April 17, 2024- Camber Pharmaceuticals is excited to introduce Fesoterodine Fumarate Extended-Release Tablets. Acco

04/09/2024

Camber Pharmaceuticals is pleased to announce the addition of Pantoprazole Sodium for Delayed-Release Oral Suspension to its current portfolio.

Pantoprazole Sodium for Delayed-Release Oral Suspension is indicated for:
* Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD) in adults and pediatric patients five years of age and older.
* Maintenance of Healing of Erosive Esophagitis and Reduction in Relapse Rates of Daytime and Nighttime Heartburn Symptoms in adult patients with GERD.
* Long- Term Treatment of Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome.

Pantoprazole Sodium for Delayed-Release 40 mg Oral Suspension is available in cartons of 30 unit dose packets.

To find out more about Pantoprazole Sodium for Delayed-Release Oral Suspension, please visit https://www.camberpharma.com/pantoprazole-dr-oral-susp

https://conta.cc/3U8WZ2O

New Product Launch   Camber Pharmaceuticals Launches Generic Protonix® Piscataway, NJ, April 9, 2024–Camber Pharmaceuticals is pleased to announce the addition of Pantoprazole Sodium for Delayed-Relea

04/04/2024

Camber Pharmaceuticals is pleased to announce the addition of Levonorgestrel and Ethinyl Estradiol Tablets USP to its current portfolio.

Levonorgestrel and Ethinyl Estradiol Tablets USP are indicated for the prevention of pregnancy in women who elect to use oral contraceptives.

Levonorgestrel and Ethinyl Estradiol Tablets USP (0.1 mg/0.02 mg) is available in boxes of 3 blister packs of 28 tablets/packet.

To find out more about Levonorgestrel and Ethinyl Estradiol Tablets USP, please visit https://www.camberpharma.com/levonorgestrel-ee

https://conta.cc/3xlZohv

New Product Launch   Camber Pharmaceuticals Launches Generic Alesse® Piscataway, NJ, April 4, 2024–Camber Pharmaceuticals is pleased to announce the addition of Levonorgestrel and Ethinyl Estradiol Ta

04/02/2024

Camber Pharmaceuticals is pleased to announce the addition of Allopurinol Tablets, USP to its current portfolio.

Allopurinol Tablets, USP are indicated for:

1) the management of patients with signs and symptoms of primary or secondary gout.

2) the management of patients with conditions requiring therapies which cause elevations of serum and urinary uric acid levels.

3) the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds specific thresholds.

Camber's Allopurinol Tablets, USP 100 mg and 300 mg are available in 100, 500 and 1000 count bottles.

To find out more about Camber's Allopurinol Tablets, USP please visit https://www.camberpharma.com/allopurinol

https://conta.cc/3xhrbjb

New Product Launch   Camber Pharmaceuticals Launches Generic Zyloprim® Piscataway, NJ, April 2, 2024 – Camber Pharmaceuticals is pleased to announce the addition of Allopurinol Tablets, USP to its cur

03/20/2024

Camber Pharmaceuticals is pleased to announce the addition of Theophylline Extended-Release Tablets to its current portfolio.

Theophylline Extended-Release Tablets are indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases.

Theophylline Extended-Release Tablets are available in 300 mg and 450 mg strengths, both in 100 count bottles.

To find out more about Theophylline Extended-Release Tablets, please visit https://www.camberpharma.com/theophylline-er

https://conta.cc/496uaYO

New Product Launch   Camber Pharmaceuticals Launches Theophylline Extended-Release Tablets Piscataway, NJ, March 20, 2024 – Camber Pharmaceuticals is pleased to announce the addition of Theophylline E

03/18/2024

Camber Pharmaceuticals is pleased to announce the addition of Gabapentin Tablets (generic for Gralise®) to its current portfolio. Camber already offers Gabapentin Tablets and Capsules (generic for Neurontin®). Generics for Gralise® and Neurontin® are not interchangeable.

Gabapentin Tablets (generic for Gralise®) are indicated for the management of Postherpetic Neuralgia (PHN).

Gabapentin Tablets (generic for Gralise®) 300 mg and 600 mg are available in 90 count bottles.

To find out more about Gabapentin Tablets, please visit https://www.camberpharma.com/gabapentintablets-gralise

https://conta.cc/4cj7qrA

New Product Launch   Camber Pharmaceuticals Launches Generic Gralise® Piscataway, NJ, March 18, 2024– Camber Pharmaceuticals is pleased to announce the addition of Gabapentin Tablets (generic for Gral